OBJECTIVE: The aim of this study was to determine the prevalence of multiple sclerosis (MS) in the population of Csongrád County, Hungary (400,128 inhabitants) and to determine the functional status (based on the Expanded Disability Status Scale; EDSS) of the patients according to the clinical forms of the disease. METHODS: The diagnosis was established with the aid of the Poser diagnostic criteria, and the degree of physical disability was determined using the Kurtzke EDSS. RESULTS: In Csongrád County, the prevalence of MS is 62/100,000. The distribution of patients according to the clinical forms of MS was as follows: 15% had the benign form, 54% had relapsing-remitting MS, 20% had secondary chronic progressive MS and 11% had the primary chronic progressive form of MS. Sixty percent of relapsing-remitting MS patients had an EDSS score of 0-4 points and 33% had an EDSS score of 4.5-6.5 points. CONCLUSION: The distribution of patients according to the clinical forms of the disease in this representative population is comparable to results in other regions of the world. Copyright 2001 S. Karger AG, Basel
OBJECTIVE: The aim of this study was to determine the prevalence of multiple sclerosis (MS) in the population of Csongrád County, Hungary (400,128 inhabitants) and to determine the functional status (based on the Expanded Disability Status Scale; EDSS) of the patients according to the clinical forms of the disease. METHODS: The diagnosis was established with the aid of the Poser diagnostic criteria, and the degree of physical disability was determined using the Kurtzke EDSS. RESULTS: In Csongrád County, the prevalence of MS is 62/100,000. The distribution of patients according to the clinical forms of MS was as follows: 15% had the benign form, 54% had relapsing-remitting MS, 20% had secondary chronic progressive MS and 11% had the primary chronic progressive form of MS. Sixty percent of relapsing-remitting MS patients had an EDSS score of 0-4 points and 33% had an EDSS score of 4.5-6.5 points. CONCLUSION: The distribution of patients according to the clinical forms of the disease in this representative population is comparable to results in other regions of the world. Copyright 2001 S. Karger AG, Basel
Authors: Anette S Fjeldstad; John McDaniel; Melissa A H Witman; Steve J Ives; Jia Zhao; John W Rose; James Hannon; D Walter Wray; Russell S Richardson Journal: J Neurol Date: 2011-05-05 Impact factor: 4.849
Authors: Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie Journal: BMC Neurol Date: 2013-09-26 Impact factor: 2.474
Authors: Tanja Daltrozzo; Alexander Hapfelmeier; Ewan Donnachie; Antonius Schneider; Bernhard Hemmer Journal: Front Neurol Date: 2018-10-30 Impact factor: 4.003
Authors: Anna Iljicsov; Dániel Milanovich; András Ajtay; Ferenc Oberfrank; Mónika Bálint; Balázs Dobi; Dániel Bereczki; Magdolna Simó Journal: PLoS One Date: 2020-07-27 Impact factor: 3.240